ClinicalTrials.gg
CompletedNCT00282984Updated Apr 5, 2017Results posted

Efficacy and Safety of Varenicline in Smokers With Cardiovascular Disease Who Wish to Quit Smoking

A Phase 3 interventional study of placebo and Varenicline in Smoking Cessation, sponsored by Pfizer. Completed at 39 sites in 15 countries. Open to participants aged 35 Years to 75 Years. Per ClinicalTrials.gov, last updated 2017-04-05.

Sponsored by Pfizer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
714
Allocation
Randomized
Ages
35 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 110 studies testing varenicline in Smoking Cessation — 5 open to participants now, 7 under way, 2 of them phase 3. Varenicline · Smoking Cessation.

Enrollment
14th of 110
714 · median 209
Started
2006
with 1 other
Phase 3
24 of 110
1 open now
Registered
11th of 110
by date
Lead sponsor
26 of 110
Pfizer

Among the 110 studies testing varenicline in Smoking Cessation, this one is the 14th largest by enrollment, is one of 2 that started in 2006, is one of 24 in phase 3, and was the 11th registered.

Smoking Cessation

1,582 studies on the registry are indexed under Smoking Cessation; 198 are open to participants now.

Browse Smoking Cessation studies →

Open to participants now

5 of the 110 studies testing varenicline in Smoking Cessation are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About varenicline

Varenicline: first FDA approval 2006 (CHANTIX), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 137 Smoking Cessation studies recruiting now, 93 (68%) set no upper age limit and 37 (27%) stop at 75 or younger; 6 take children under 18; 41 take healthy volunteers.

This study: 35 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 110 studies testing varenicline in Smoking Cessation, or all of them as a file.
02

Study summary

The primary purpose of this study is to determine whether or not varenicline will help people with cardiovascular disease quit smoking and to confirm it is safe in these patients.

03

Conditions studied

  • Smoking Cessation

Browse trials for

04

Who can participate

Ages eligible
35 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must have stable, documented cardiovascular disease (including at least one of the following diagnosed > 2 months prior to the Screening visit - angina, myocardial infarction (MI), revascularization, (TIA), and peripheral vascular disease (PVD).
  • Participants that smoke > 10 cigarettes / day.

Exclusion criteria

Exclusion Criteria:

  • Participants with unstable cardiovascular disease
  • Cardiovascular events in the past 2 months
  • Moderate or severe (COPD)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
714 participants (actual)

Study arms

  • Placebo comparator
    placebo

    Drug: placebo

  • Experimental
    varenicline

    Drug: Varenicline

Interventions

  • Drugplacebo

    1 mg placebo twice daily by mouth for 12 weeks

  • 1 mg twice daily by mouth for 12 weeks

    Also known as: Chantix, Champix

06

What researchers measure

Primary outcomes

  1. Number of Responders With Carbon Monoxide (CO) Confirmed 4-week Continuous Quit Rate (CQR) for Last 4 Weeks of Treatment (Trtmt)

    Participants considered Responders (4-week CQR \<=10 parts per million \<ppm\>) through reports of cigarette or other nicotine use since last study visit, confirmed by measurement of end-expiratory exhaled carbon monoxide (CO). If any CO measurement at a particular timepoint was \>10 ppm, subject was considered to be Non-Responder at that timepoint.

    Time frame: weeks 9 through 12

Secondary outcomes

  1. Number of Responders With Continuous Abstinence (CA) Through Week 52

    Responders: participants who remained abstinent based on 'since the last contact' question in Nicotine Use Inventory 1) "Has participant smoked any cigarettes (even a puff) since last contact?" = No AND 2) "Has participant used any other tobacco products... since last contact?" = No. Participant a non-responder if expired CO \> 10 ppm.

    Time frame: Week 9 through Week 52

  2. Number of Long-Term Quit Responders

    Responders: participants were considered Long Term Quit responders if 1) they were responders for the primary endpoint (the 4-week CQR for Weeks 9-12) and 2) had no more than 6 days of smoking from Week 12 through the given visit.

    Time frame: Week 9 through Week 52

  3. Number of Participants With a Seven-Day Point Prevalence of Abstinence at Week 12

    Responders: abstinence in previous seven days, defined in the non-treatment follow-up as: 1) "Has the participant smoked any cigarettes in the last 7 days?" = No AND 2) "Has the participant used any other tobacco products in the last 7 days?" = No. Participant a non-responder if expired CO \> 10 ppm.

    Time frame: Week 12

  4. Number of Participants With a Seven-Day Point Prevalence of Abstinence at Week 24

    Responders: abstinence in previous seven days, defined in the non-treatment follow-up as: 1) "Has the participant smoked any cigarettes in the last 7 days?" = No AND 2) "Has the participant used any other tobacco products in the last 7 days?" = No. Participant a non-responder if expired CO \> 10 ppm.

    Time frame: Week 24

  5. Number of Participants With a Seven-Day Point Prevalence of Abstinence at Week 52

    Responders: abstinence in previous seven days, defined in the non-treatment follow-up as: 1) "Has the participant smoked any cigarettes in the last 7 days?" = No AND 2) "Has the participant used any other tobacco products in the last 7 days?" = No. Participant a non-responder if expired CO \> 10 ppm.

    Time frame: Week 52

  6. Number of Participants With a 4 Week Point Prevalence of Smoking Cessation

    Responders: participants with abstinence during the last 4 weeks of non-treatment based on answering 'no' to both of the two 'last 4 week' questions in the Nicotine Use Inventory (NUI). NUI collected information of cigarette or other nicotine use during the study.

    Time frame: Week 48 through Week 52 (final 4 weeks of non-treatment period [pd])

  7. Number of Responders With Continuous Abstinence (CA) Through Week 24

    Responders: participants who remained abstinent based on 'since the last contact' question in Nicotine Use Inventory 1) "Has participant smoked any cigarettes (even a puff) since the last contact?" = No AND 2) "Has participant used any other tobacco products... since the last contact?" = No. Non- responder if the expired CO \> 10 ppm at any given timepoint.

    Time frame: Week 9 through Week 24

  8. Cigarettes Smoked Per Day

    Cigarettes smoked each day during the first 3 weeks of the treatment phase.

    Time frame: Day 21

  9. Number of Long-Term Quit Responders From Week 9 Through Week 24

    Responders: participants were considered Long Term Quit Responders if 1) they were responders for the primary endpoint (the 4-week CQR for Weeks 9-12) and 2) had no more than 6 days of smoking from Week 12 through the given visit.

    Time frame: Week 9 through Week 24

07

Results

Posted Apr 29, 2009

Participant flow

The study was conducted in outpatients. The target population was cigarette smokers with cardiovascular disease drawn from the communities surrounding the participating clinics.

Participant flow — Overall Study
MilestoneVarenicline (Var)Placebo (Pbo)
Started353350
Completed302289
Not completed5161
Withdrew: Death25
Withdrew: Adverse event85
Withdrew: Lack of efficacy02
Withdrew: Lost to follow-up1410
Withdrew: Withdrawal by participant2234
Withdrew: Participant stopped study medication22
Withdrew: Participant only allowed phone follow-up01
Withdrew: Participant used antipsychosis meds01
Withdrew: Lack of motivation10
Withdrew: In prison01
Withdrew: Protocol violation20

Outcome measures

PrimaryNumber of Responders With Carbon Monoxide (CO) Confirmed 4-week Continuous Quit Rate (CQR) for Last 4 Weeks of Treatment (Trtmt)

Participants considered Responders (4-week CQR \<=10 parts per million \<ppm\>) through reports of cigarette or other nicotine use since last study visit, confirmed by measurement of end-expiratory exhaled carbon monoxide (CO). If any CO measurement at a particular timepoint was \>10 ppm, subject was considered to be Non-Responder at that timepoint.

Time frame:
weeks 9 through 12
Reported as:
Number · participants
Number of Responders With Carbon Monoxide (CO) Confirmed 4-week Continuous Quit Rate (CQR) for Last 4 Weeks of Treatment (Trtmt)
participantsVarenicline (Var)Placebo (Pbo)
responders16750
non-responders186300
Statistical analysis
  • Varenicline (Var) vs Placebo (Pbo) · Regression, Logistic · p = <0.0001 (To preserve type I family-wise error rate of 0.05, used step-down procedure to analyze primary \& 2 key secondary endpoints. Hierarchy of comparisons: 1) 4-week CQR for Weeks 9 thru 12, 2) CA at Week 52, 3) the Long Term Quit Rate (LTQR) thru Week 52.) · Odds ratio (or): 6.05 · 95% CI 4.13 to 8.86Logistic regression model fitted to primary endpoint \& key secondary endpoints; included main effects of trtmt group and center as independent var.
SecondaryNumber of Responders With Continuous Abstinence (CA) Through Week 52

Responders: participants who remained abstinent based on 'since the last contact' question in Nicotine Use Inventory 1) "Has participant smoked any cigarettes (even a puff) since last contact?" = No AND 2) "Has participant used any other tobacco products... since last contact?" = No. Participant a non-responder if expired CO \> 10 ppm.

Time frame:
Week 9 through Week 52
Reported as:
Number · participants
Number of Responders With Continuous Abstinence (CA) Through Week 52
participantsVarenicline (Var)Placebo (Pbo)
responders7026
non-responders283324
Statistical analysis
  • Varenicline (Var) vs Placebo (Pbo) · Regression, Logistic · p = <0.0001 (To preserve type I family-wise error rate of 0.05, a step-down procedure was used for the analysis of primary \& 2 key secondary endpts. Hierarchy of comparisons: 1) 4-week CQR for Weeks 9 through 12, 2) CA at Week 52, 3) LTQR through Week 52.) · Odds ratio (or): 3.19 · 95% CI 1.97 to 5.18Logistic regression model fitted to primary endpoint \& key secondary endpoints; included main effects of treatment group \& center as independent var.
SecondaryNumber of Long-Term Quit Responders

Responders: participants were considered Long Term Quit responders if 1) they were responders for the primary endpoint (the 4-week CQR for Weeks 9-12) and 2) had no more than 6 days of smoking from Week 12 through the given visit.

Time frame:
Week 9 through Week 52
Reported as:
Number · participants
Number of Long-Term Quit Responders
participantsVarenicline (Var)Placebo (Pbo)
responders8034
non-responders273316
Statistical analysis
  • Varenicline (Var) vs Placebo (Pbo) · Regression, Logistic · p = <0.0001 (To preserve type I family-wise error rate of 0.05, a step-down procedure was used for the analysis of primary \& 2 key secondary endpoints. Hierarchy of comparisons: 1) 4-week CQR for Weeks 9 through 12, 2) CA at Week 52, 3) the LTQR through Week 52.) · Odds ratio (or): 2.82 · 95% CI 1.82 to 4.38Logistic regression model fitted to primary endpoint \& key secondary endpoints; included main effects of trtmt group and center as independent var.
SecondaryNumber of Participants With a Seven-Day Point Prevalence of Abstinence at Week 12

Responders: abstinence in previous seven days, defined in the non-treatment follow-up as: 1) "Has the participant smoked any cigarettes in the last 7 days?" = No AND 2) "Has the participant used any other tobacco products in the last 7 days?" = No. Participant a non-responder if expired CO \> 10 ppm.

Time frame:
Week 12
Reported as:
Number · participants
Number of Participants With a Seven-Day Point Prevalence of Abstinence at Week 12
participantsVarenicline (Var)Placebo (Pbo)
responders19265
non-responders161285
Statistical analysis
  • Varenicline (Var) vs Placebo (Pbo) · Regression, Logistic · p = <0.0001 · Odds ratio (or): 5.97 · 95% CI 4.17 to 8.56
SecondaryNumber of Participants With a Seven-Day Point Prevalence of Abstinence at Week 24

Responders: abstinence in previous seven days, defined in the non-treatment follow-up as: 1) "Has the participant smoked any cigarettes in the last 7 days?" = No AND 2) "Has the participant used any other tobacco products in the last 7 days?" = No. Participant a non-responder if expired CO \> 10 ppm.

Time frame:
Week 24
Reported as:
Number · participants
Number of Participants With a Seven-Day Point Prevalence of Abstinence at Week 24
participantsVarenicline (Var)Placebo (Pbo)
responders12457
non-responders229293
Statistical analysis
  • Varenicline (Var) vs Placebo (Pbo) · Regression, Logistic · p = <0.0001 · Odds ratio (or): 2.93 · 95% CI 2.03 to 4.23
SecondaryNumber of Participants With a Seven-Day Point Prevalence of Abstinence at Week 52

Responders: abstinence in previous seven days, defined in the non-treatment follow-up as: 1) "Has the participant smoked any cigarettes in the last 7 days?" = No AND 2) "Has the participant used any other tobacco products in the last 7 days?" = No. Participant a non-responder if expired CO \> 10 ppm.

Time frame:
Week 52
Reported as:
Number · participants
Number of Participants With a Seven-Day Point Prevalence of Abstinence at Week 52
participantsVarenicline (Var)Placebo (Pbo)
responders10262
non-responders251288
Statistical analysis
  • Varenicline (Var) vs Placebo (Pbo) · Regression, Logistic · p = 0.0003 · Odds ratio (or): 1.93 · 95% CI 1.34 to 2.77
SecondaryNumber of Participants With a 4 Week Point Prevalence of Smoking Cessation

Responders: participants with abstinence during the last 4 weeks of non-treatment based on answering 'no' to both of the two 'last 4 week' questions in the Nicotine Use Inventory (NUI). NUI collected information of cigarette or other nicotine use during the study.

Time frame:
Week 48 through Week 52 (final 4 weeks of non-treatment period [pd])
Reported as:
Number · participants
Number of Participants With a 4 Week Point Prevalence of Smoking Cessation
participantsVarenicline (Var)Placebo (Pbo)
Number of Participants With a 4 Week Point Prevalence of Smoking Cessation9957
Statistical analysis
  • Varenicline (Var) vs Placebo (Pbo) · Regression, Logistic · p = 0.0001 · Odds ratio (or): 2.05 · 95% CI 1.41 to 2.97
SecondaryNumber of Responders With Continuous Abstinence (CA) Through Week 24

Responders: participants who remained abstinent based on 'since the last contact' question in Nicotine Use Inventory 1) "Has participant smoked any cigarettes (even a puff) since the last contact?" = No AND 2) "Has participant used any other tobacco products... since the last contact?" = No. Non- responder if the expired CO \> 10 ppm at any given timepoint.

Time frame:
Week 9 through Week 24
Reported as:
Number · participants
Number of Responders With Continuous Abstinence (CA) Through Week 24
participantsVarenicline (Var)Placebo (Pbo)
Number of Responders With Continuous Abstinence (CA) Through Week 2410034
Statistical analysis
  • Varenicline (Var) vs Placebo (Pbo) · Regression, Logistic · p = <0.0001 · Odds ratio (or): 3.86 · 95% CI 2.51 to 5.93
SecondaryCigarettes Smoked Per Day

Cigarettes smoked each day during the first 3 weeks of the treatment phase.

Time frame:
Day 21
Reported as:
Mean · cigarettes per day
Cigarettes Smoked Per Day
cigarettes per dayVarenicline (Var)Placebo (Pbo)
Baseline22.2 ± 10.022.9 ± 10.9
Day 117.6 ± 9.419.1 ± 10.0
Day 216.8 ± 8.818.4 ± 9.6
Day 315.8 ± 9.218.0 ± 10.0
Day 415.7 ± 8.917.1 ± 9.6
Day 515.1 ± 8.816.3 ± 8.9
Day 614.4 ± 8.416.0 ± 8.9
Day 713.8 ± 8.615.1 ± 8.8
Day 811.7 ± 9.212.3 ± 10.5
Day 99.5 ± 7.510.9 ± 9.5
Day 108.9 ± 7.210.6 ± 8.6
Day 118.9 ± 7.310.4 ± 8.4
Day 128.7 ± 7.510.5 ± 8.3
Day 138.8 ± 7.110.3 ± 8.2
Day 149.3 ± 7.410.7 ± 8.6
Day 158.9 ± 7.611.2 ± 9.1
Day 168.8 ± 7.111.0 ± 8.7
Day 178.3 ± 6.410.6 ± 8.2
Day 188.2 ± 6.910.3 ± 8.8
Day 197.8 ± 6.710.3 ± 8.4
Day 207.9 ± 6.110.6 ± 8.3
Day 217.2 ± 6.39.3 ± 8.1
SecondaryNumber of Long-Term Quit Responders From Week 9 Through Week 24

Responders: participants were considered Long Term Quit Responders if 1) they were responders for the primary endpoint (the 4-week CQR for Weeks 9-12) and 2) had no more than 6 days of smoking from Week 12 through the given visit.

Time frame:
Week 9 through Week 24
Reported as:
Number · participants
Number of Long-Term Quit Responders From Week 9 Through Week 24
participantsVarenicline (Var)Placebo (Pbo)
responders11742
non-responders236308
Statistical analysis
  • Varenicline (Var) vs Placebo (Pbo) · Regression, Logistic · p = <0.0001 · Odds ratio (or): 3.85 · 95% CI 2.58 to 5.75

Adverse events

Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Varenicline (Var)———
Placebo (Pbo)———
Most frequent serious events
Showing 10 of 48
Most frequent serious events
EventVarenicline (Var)Placebo (Pbo)
Angina pectorisCardiac disorders1/3532/350
Atrial fibrillationCardiac disorders1/3532/350
Chest painGeneral disorders2/3532/350
Acute myocardial infarctionCardiac disorders2/3531/350
Cerebrovascular accidentNervous system disorders2/3530/350
AnaemiaBlood and lymphatic system disorders0/3531/350
Acute coronary syndromeCardiac disorders0/3531/350
Cardiac failureCardiac disorders1/3531/350
Cardiac failure congestiveCardiac disorders0/3531/350
Myocardial infarctionCardiac disorders1/3531/350
Most frequent other events
Showing 10 of 30
Most frequent other events
EventVarenicline (Var)Placebo (Pbo)
NauseaGastrointestinal disorders104/35330/350
HeadacheNervous system disorders45/35339/350
InsomniaPsychiatric disorders42/35323/350
NasopharyngitisInfections and infestations23/35330/350
VomitingGastrointestinal disorders29/3534/350
Abnormal dreamsPsychiatric disorders28/3536/350
FatigueGeneral disorders25/35314/350
ConstipationGastrointestinal disorders23/3537/350
DiarrhoeaGastrointestinal disorders22/35318/350
DizzinessNervous system disorders22/35316/350

Baseline characteristics

Age, Continuous
Age, Continuous(years)Varenicline (Var)Placebo (Pbo)Total
Mean57.0 ± 8.656.0 ± 8.456.5 ± 8.5
Sex: Female, Male
Sex: Female, Male(Participants)Varenicline (Var)Placebo (Pbo)Total
Female8763150
Male266287553
08

Study locations

39 sites
  • Pfizer Investigational Site
    Hartford, Connecticut 06102-5037, United States
  • Pfizer Investigational Site
    Boston, Massachusetts 02114, United States
  • Pfizer Investigational Site
    Madison, Wisconsin 53711, United States
  • Pfizer Investigational Site
    Capital Federal, Buenos Aires 1181, Argentina
  • Pfizer Investigational Site
    Ciudad de Buenos Aires, Buenos Aires 1221, Argentina
  • Pfizer Investigational Site
    Concord, New South Wales 2139, Australia
  • Pfizer Investigational Site
    Herston, Queensland 4029, Australia
  • Pfizer Investigational Site
    Porto Alegre, RS 90610-000, Brazil
  • Pfizer Investigational Site
    São Paulo, SP 05403-904, Brazil
  • Pfizer Investigational Site
    London, Ontario N6C 5J1, Canada
  • Pfizer Investigational Site
    Ottawa, Ontario K1Y 4W7, Canada
  • Pfizer Investigational Site
    Drummondville, Quebec J2B 7T1, Canada
  • Pfizer Investigational Site
    Quebec, G1V 4M6, Canada
  • Pfizer Investigational Site
    Brno, 625 00, Czech Republic
  • Pfizer Investigational Site
    Praha 2, 120 00, Czech Republic
  • Pfizer Investigational Site
    Aarhus C, DK-8000, Denmark
  • Pfizer Investigational Site
    Hellerup, DK-2900, Denmark
  • Pfizer Investigational Site
    Caen, 14033, France
  • Pfizer Investigational Site
    Marseille, 13015, France
  • Pfizer Investigational Site
    Toulouse Cedex, 31059, France
  • Pfizer Investigational Site
    Berlin, 10787, Germany
  • Pfizer Investigational Site
    Goettingen, 37075, Germany
  • Pfizer Investigational Site
    Tuebingen, 72076, Germany
  • Pfizer Investigational Site
    Athens, 11528, Greece
  • Pfizer Investigational Site
    Pireaus, 18526, Greece
  • Pfizer Investigational Site
    Seoul, Korea 152-703, Korea, Republic of
  • Pfizer Investigational Site
    Seoul, 110-799, Korea, Republic of
  • Pfizer Investigational Site
    Seoul, 135-720, Korea, Republic of
  • Pfizer Investigational Site
    Seoul, 138-736, Korea, Republic of
  • Pfizer Investigational Site
    Tlalpan, Mexico D.F. 14080, Mexico
  • Pfizer Investigational Site
    Monterrey, Nuevo León, Mexico
  • Pfizer Investigational Site
    Amsterdam, 1066 EC, Netherlands
  • Pfizer Investigational Site
    Zuthpen, 7207 BA, Netherlands
  • Pfizer Investigational Site
    Taipei, 11217, Taiwan
  • Pfizer Investigational Site
    Tau-Yuan Hsien, 333, Taiwan
  • Pfizer Investigational Site
    Carshalton, Surrey SM5 1AA, United Kingdom
  • Pfizer Investigational Site
    Bradford, West Yorkshire BD9 6RJ, United Kingdom
  • Pfizer Investigational Site
    Leicester, LE1 5WW, United Kingdom
  • Pfizer Investigational Site
    Paisley, PA2 9PN, United Kingdom
09

References and documents

Publications

  • Rigotti NA, Pipe AL, Benowitz NL, Arteaga C, Garza D, Tonstad S. Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: a randomized trial. Circulation. 2010 Jan 19;121(2):221-9. doi: 10.1161/CIRCULATIONAHA.109.869008. Epub 2010 Jan 4. PubMed 20048210 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2006, a primary completion of Nov 2007 and a completion of Aug 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2009, 1 year 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 26, 2006
First posted
Jan 27, 2006
Start
Feb 2006
Primary completionActual
Nov 2007
CompletionActual
Aug 2008
Results first posted
Apr 29, 2009
Last update
Apr 5, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 5, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00282984
Lead sponsor
Pfizer
First posted
Jan 27, 2006
Start date
Feb 2006
Primary completion
Nov 2007
Completion
Aug 2008
Results posted
Apr 29, 2009
Last update
Apr 5, 2017

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Varenicline

Start the discussion